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 ABSTRACT 
 
The use of platelet rich plasma (PRP) in sports medicine has increased dramatically 
recently but there are still doubts towards its efficacy that likely stem from the wide 
variety between PRP samples and products. To further define PRP, this study aimed to 
test whether its composition was altered if PRP or the blood used to produce PRP, 
remained out at room temperature before use. Another aim was to establish if a 
manual platelet count would adequately quantify platelet concentration compared to 
using automated methods. All types of PRP product tested remained stable, according 
to growth factor and cytokine measurements, for up to four hours when stored at room 
temperature. No significant differences were found in platelet concentrations obtained 
from automated or manual methods. The results found confirm the ease of verifying 
platelet concentration manually and that PRP can be used in orthopedic and surgical 
situations without worry of product degradation.  
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CHAPTER 1 
BACKGROUND 
 
 Platelet rich plasma (PRP) is primarily used to promote healing or as a 
bioscaffold in areas of medicine such as dental surgery [17, 20], soft tissue injuries 
[16, 18], orthopedic surgery [21, 23], wound healing [12], and veterinary medicine [4, 
25]. Despite its extensive use, there are still doubts about the clinical efficacy of PRP 
[19, 22, 26]. One of the difficulties in interpreting clinical outcome data is variations 
in the type and consistency of PRP that is generated between patients due to biological 
variability [5, 14] and variations between PRP products made from the numerous 
manufacturing kits available [5, 6]. There are classification schemes to categorize the 
various types of PRP [2, 8, 9] which can broadly be categorized as low leukocyte PRP 
(Llo PRP) or high leukocyte PRP (Lhi PRP). 
  PRP can be a point of care therapy, prepared and used immediately such as in 
cases to treat knee pain, or it can be used in surgical procedures. Each clinical setting 
and operating theater has its own policy for generation of PRP. In some instances, 
blood is drawn by a phlebotomists and processed in the hospital laboratory, and in 
others scenarios, the primary attending physician or their assistant would draw the 
blood and process it to generate PRP patient-side [10, 21]. These various situations 
could result in blood or the resultant PRP retained at room temperature for minutes to 
several hours prior to administration to the patient.   
 The primary aim of this study was to test if room temperature retention of 
blood or PRP for various time intervals affects platelet degranulation.  Concentration 
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of platelet-derived growth factors were used as a surrogate marker of platelet 
degranulation in blood, Llo PRP, and Lhi PRP retained at room temperature for up to 4 
hours. A second aim was to determine if manual platelet counts were an accurate 
reflection of automated counts. The use of manual platelet counts would provide a cost 
effective alternative to automated platelet counting for research studies. The outcomes 
of these experiments should provide immediately relevant information for the clinical 
application of PRP.   
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CHAPTER 2 
EVALUATION OF PRP AND GROWTH FACTORS 
 
Methods and Materials 
 Blood collection and generation of PRP - Venous blood (100mls) was 
collected from healthy human volunteers (n=5) into acid citrate dextrose (ACD) 
anticoagulant to a final concentration of 1%. Three 15mL aliquots were placed into 
disposable syringes used to generate Llo PRP (Autologous Conditioned Serum Double 
Syringe, Arthrex, Naples, FL) and three 20mL aliquots were placed into the disposable 
used to generate Lhi PRP (SmartPReP 2, Harvest Technologies, Plymouth, MA). To 
test the effects of retaining blood at room temperature before processing PRP, one 
sample from each Llo PRP and Lhi PRP group was processed immediately, the next 
sample was processed after being retained at room temperature for two hours, and the 
final sample was processed after four hours at room temperature.  At the end of each 
retention time, the samples were used to generate PRP according to the respective 
manufacturer’s directions. Aliquots of resultant PRPs were immediately frozen at -
80°C for future analyses. Remaining PRP samples were allowed to sit at room 
temperature in their disposable devices with aliquots removed at one, two and four 
hours and frozen for future analysis. No PRP sample was buffered or activated after 
processing. Figure 1 is provided as a schematic outlining sample collection and 
preparation. 
 Automated and manual counts - A complete blood count (CBC) was 
performed on the initial samples of venous blood, Llo PRP, and Lhi PRP samples. A 
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manual platelet count, using a modified Giemsa stain, was performed on smears of all 
whole blood samples taken as well as every PRP sample made at each of the time 
points. All slides were microscopically examined at 10x objective (Figure 2a) to 
identify an ideal area of the smear to perform a platelet count. The magnification was 
then increased to the 100x oil immersion where the total number of platelets was 
counted in ten of these high-powered fields of view (Figure 2b). The average number 
of platelets per high-powered field was determined and multiplied by 15 to find the 
total number of platelets (thou/ul) for the sample [13]. This data was used to compare 
the reliability of manual platelet counts versus automated counts and to ensure that at 
each time point PRP was produced.   
 
 
  
 
             
 
 
 
 
 
 
Figure 2: (A) Thin edge of a prepared blood smear under 10x objective where it is 
pertinent to look for platelet clumping or other abnormalities. This area is free of 
platelet clumps and the red blood cells are evenly spread out, indicating it is an ideal 
area to perform a platelet count. Once the blood smear is scanned at low power, (B) 
the area is observed at 100x oil immersion where the average number of platelets 
(arrows) per high-powered field is counted.    
 
 
A B 
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 Growth factor and catabolic cytokine measurements – Blood and PRP samples 
were thawed and centrifuged at 12000g for 15 minutes to pellet cell debris. 
Transforming growth factor-beta 1 (TGF-β1) concentration was determined using the 
TGF-β1 Emax ImmunoAssay System (Promega Corporation, Madison, Wisconsin). 
TGF-β1 was chosen as an anabolic growth factor to measure in the PRP samples 
because of the multiple effects it has in healing. It has been shown to stimulate 
undifferentiated mesenchymal cell proliferation, regulate endothelial, fibroblastic and 
osteoblastic mitogenesis, regulate collagen synthesis, stimulate endothelial chemotaxis 
and angiogenesis, stimulate synthesis of extracellular matrix in cartilage, and decrease 
catabolic activity of interluekin-1 (IL-1) and matrix metalloproteinases (MMPs) [3, 7, 
11]. It has also been shown to correlate to platelet concentration [24]. Matrix 
metalloproteinase nine (MMP-9) concentration was determined using the MMP-9 
Biotrak Activity Assay (GE Healthcare Biosciences, Piscataway, New Jersey). MMP-
9 was measured as an indicator of catabolic factors in PRP because it is a known 
collagenase [5, 27], shown to be linked to poor healing [28] and has been correlated to 
WBC levels [24].  TGF-β1 and MMP-9 were evaluated in each sample to measure any 
increase or decease in anabolic or catabolic factors due to the time samples remained 
at room temperature. Samples were measured in duplicate using a multiple detection 
plate reader (Tecan SAFIRE, Durham, North Carolina).  
 Statistical analyses - Platelet concentration values were normally distributed 
on a histogram so a paired t-test was performed comparing automated and manual 
methods of obtaining a platelet concentration in whole blood, Llo PRP, and Lhi PRP. A 
paired t-test was also used to compare platelet, TGF-β1, and MMP-9 concentrations 
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between LloPRP and LhiPRP. TGF-β1 concentrations were not normally distributed so 
a Kruskal-Wallis one-way ANOVA followed by a Dunn’s all-pairwise comparison 
was used to compare the TGF-β1 concentrations in LloPRP and LhiPRP, separately, at 
each time point. A Kruskal-Wallis was also run on TGF-β1 concentrations found in 
LloPRP and LhiPRP produced from blood that was retained at room temperature. 
MMP-9 concentrations were normally distributed so a one-way ANOVA with a Tukey 
all-pairwise comparison was used to compare MMP-9 concentrations in LloPRP and 
LhiPRP, separately, at each time point. A one-way ANOVA was also performed on 
MMP-9 concentrations found in LloPRP and LhiPRP that had been produced from 
blood that was retained at room temperature. Statistical analyses were performed using 
Statistix 9 software (Analytical Software, Tallahassee, Florida). A p-value of <0.05 
was considered significant. 
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Results 
 Validation of PRP generation – Both systems successfully generated PRP. 
Platelet concentration in LloPRP had an average of a 1.98±0.14 fold increase and a 
0.47±0.07 fold change in WBC from baseline. LhiPRP had an average of a 3.06±0.24 
fold increase in platelet concentration with a 1.05±0.17 fold change in WBC from 
baseline. LhiPRP had a significantly increased platelet concentration (p= 0.001) and 
WBC levels (p= 0.020) when compared to LloPRP. However, no difference was seen 
between TGF-β1 (p= 0.063) or MMP-9 (p= 0.365) concentrations between the two 
PRP products.  
 Stability of platelets in PRP retained at room temperature – TGFβ-1 
concentrations were not significantly different in PRP products processed immediately 
or that were retained at room temperature for up to four hours (Figure 3). MMP-9 
concentrations were also similar between immediately processed PRP and PRP 
retained at room temperature (Figure 4).  
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Figure 3: Concentration of TGF-β1 in (A) LloPRP and (B) LhiPRP processed 
immediately or retained at room temperature for 1, 2, or 4 hours after processing. Bars 
represent mean (N=5) ± SE. Significance was determined using a Kruskal-Wallis one-
way ANOVA. LloPRP p = 0.966, LhiPRP p = 0.986. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Concentration of MMP-9 in (A) LloPRP and (B) LhiPRP processed 
immediately or retained at room temperature for 1, 2, or 4 hours after processing. Bars 
represent mean (N=5) ± SE. Significance was determined using a one-way ANOVA. 
LloPRP p = 0.187, LhiPRP p = 0.490. 
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 Stability of platelets in blood retained at room temperature – Blood samples 
were retained at room temperature for up to 4 hours prior to producing PRP. Neither 
TGFβ-1 (Figure 5) nor MMP-9 concentrations (Figure 6) changed significantly over 
time when blood was retained at room temperature prior to processing the PRP.  
 
 
 
Figure 5: Concentration of TGF-β1 in (A) LloPRP and (B) LhiPRP processed 
immediately or that was processed with blood retained at room temperature for 2 or 4 
hours. Bars represent mean (N=5) ± SE. Significance was determined using a Kruskal-
Wallis one-way ANOVA. LloPRP p = 0.833, LhiPRP p = 0.894 
 
 
 
 
 
Figure 6: Concentration of MMP-9 in (A) LloPRP and (B) LhiPRP processed 
immediately or that was processed with blood that was retained at room temperature 
for 2 or 4 hours. Bars represent mean (N=5) ± SE. Significance was determined using 
a one-way ANOVA. LloPRP p = 0.362, LhiPRP p = 0.516 
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 Automatic vs. manual platelet count – A question this study posed was whether 
a manual platelet count was adequate to qualify a sample as PRP when compared to an 
automated platelet count. Our results show a significant difference between the 
automated and manual platelet counts (p = 0.05) for whole blood samples (n=5). 
However, we believe that the manual count is more accurate as platelet clumping was 
seen on two samples in the automated count, which contributed to falsely lower 
reported platelet concentrations. Manual platelet counts for both LloPRP and LhiPRP 
were adequate (p = 0.61 and p = 0.36 respectively) when compared to the automated 
platelet counts performed (Table 1). 
 
 
 
 
 
 
Table 1: Platelet concentrations in whole blood, LloPRP, and LhiPRP (N=5). A paired 
t-test was performed to compare results obtained from an automated platelet count to 
those obtained from a manual count. Superscript letters indicate significant difference 
between automated or manual platelet concentration within each category. 
Mean ± SD Range Mean ± SD Range
Venous blood 111.8 ± 59.47 54-202 210.9 ± 59.36 144-297
LloPRP 421.4 ± 132.8 319-620 410.1 ± 94.18 318-543
LhiPRP 634.4 ± 88.77 517-766 635.4 ± 176.61 491-933
Automated Count Manual Count
Platelet concentration (thou/uL)
a
loPRP 
LhiPRP 
c c
d d
b
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CHAPTER 3 
DISCUSSION 
 
 The purpose of this study was to better define both LloPRP and LhiPRP by 
characterizing any changes that may occur to PRP due to extended preparation times. 
This level of understanding is necessary due to the lack of a consistent definition for 
PRP and the multiple methods available for producing PRP. By better understanding 
the stability of growth factors in different types of PRP, it will be possible to provide 
more dependable treatment of lesions with PRP. This knowledge will also help to 
streamline future studies of PRP by eliminating one of the potential areas of biological 
variability found in PRP.  
 The main limitation of this study is the small sample size. However, the 
increased variability that occurs when producing PRP, as seen by the large range in 
growth factor concentration in this study, has also been shown in multiple other 
studies despite having used a larger sample size [2, 5, 14]. Another potential limitation 
of the study could be that only one growth factor, TGF-β1, and one catabolic cytokine, 
MMP-9, were used as surrogate measures to represent overall growth factor stability. 
For the sake of time and cost, we decided to use only one type ELISA to measure 
growth factors, choosing TGF-β1 because it has been shown to correlate to platelet 
concentrations [6, 14, 24]. MMP-9 was chosen to be measured as an indicator of 
catabolic factors in PRP because it is a known collagenase [5, 27] linked to poor 
healing [28] and has been correlated to WBC levels [24].   
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 This study indicates that performing a manual platelet count on whole blood 
and PRP samples is adequate for classifying PRP production. Our study showed that 
manual platelet counts may be more beneficial than automated counts as the 
automated counts can be artificially low due to platelet clumping which has been 
shown to occur as early as one hour after blood collection in spite of what type of 
anticoagulant is used when collecting venous blood [15]. It is necessary to verify that 
PRP has been produced as multiple studies have shown that platelet concentration is 
highly variable, changing between people, PRP production systems, and even between 
multiple blood draws on the same patient [5, 14]. Being able to use a manual platelet 
count to verify PRP is more readily available to clinicians, less expensive, and more 
quickly performed than automated counts.  
 This study also found that growth factors remain stable in both LloPRP and 
LhiPRP when either the blood is retained at room temperature for up to four hours 
before production of PRP or if the PRP itself is retained at room temperature for up to 
four hours before being utilized. To the authors knowledge, this is the first such type 
of study performed on PRP. The results are important to note because this eliminates 
one area of possible variability in PRP. Patients receiving PRP treatments that have 
had a delay in processing; e.g. when used during surgery or when placed in 
bioscaffolds [1, 10], are receiving a product with similar qualities as PRP that has not 
been delayed in production. Knowing that growth factors remain stable in PRP for up 
to four hours helps standardize and define PRP for future clinical studies, removing a 
potential area of variability seen between basic science studies and clinical studies.  
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 This study illustrated that growth factors in both LloPRP and LhiPRP are stable 
for up to four hours and it is acceptable to use those PRP products without worrying 
about potential variability in the product. This becomes most important when PRP is 
used in surgical situations and there may be a delay in the processing or use of 
prepared PRP. However, it is still important to ensure that the product made is actually 
PRP as this study and many others have shown a great deal of variability between 
patients and PRP systems [5, 14]. The fact that growth factors in PRP are stable for 
four hours takes away some of the variability between clinical studies and allows for 
clinicians to focus on other areas of difference between PRP products. The 
standardization and better definition of PRP will only lead to better studies and more 
comprehensive results.   
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